Physician profile
Ronald E Warwar
NPI 1881698363
$1,529.20
in general payments reported to CMS, 2019-2025
11 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $50.00 · 2021: $220 · 2022: $188 · 2023: $382 · 2024: $274 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $237.58 | 2021-2023 | Tepezza |
| Amgen INC. | $231.60 | 2024-2025 | Tepezza |
| Glaukos Corporation | $210.58 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $198.21 | 2023 | Miebo |
| Johnson & Johnson Vision Care, INC. | $157.71 | 2019-2023 | |
| Alcon Vision LLC | $155.90 | 2022-2025 | Clareon |
| Sight Sciences, INC. | $97.70 | 2021 | |
| Alimera Sciences, INC. | $90.18 | 2019 | |
| Aerie Pharmaceuticals, INC. | $74.99 | 2021 | |
| Carl Zeiss Meditec, INC. | $50.00 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $24.75 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Warwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.